<?xml version="1.0" encoding="UTF-8"?>
<xmi:XMI xmlns:provenance="http:///de/fraunhofer/scai/bio/extraction/types/meta/provenance.ecore" xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:meta2="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/meta.ecore" xmlns:meta="http:///de/fraunhofer/scai/bio/extraction/types/meta.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:container="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/container.ecore" xmlns:text="http:///de/fraunhofer/scai/bio/extraction/types/text.ecore" xmlns:structure="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/structure.ecore" xmlns:image="http:///de/fraunhofer/scai/bio/extraction/types/image.ecore" xmlns:documentelement="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <meta:Person xmi:id="1" surname="uimahpc"/>
    <meta:Person xmi:id="6" surname="uimahpc"/>
    <meta:Person xmi:id="11" surname="msood"/>
    <provenance:AgentProvenance xmi:id="16" user="1"/>
    <provenance:AgentProvenance xmi:id="18" user="6"/>
    <provenance:AgentProvenance xmi:id="20" user="11"/>
    <provenance:ActivityProvenance xmi:id="22" componentId="de.fraunhofer.scai.bio.uima.core.reader.XCasMessageReader" startedAtTime="1172" endedAtTime="1179" version="7.1-SNAPSHOT" parameters="147 151 155 159 163 167 171 1186" wasAssociatedWith="16"/>
    <provenance:ActivityProvenance xmi:id="39" componentId="de.fraunhofer.scai.bio.uima.core.reader.XCasMessageReader" startedAtTime="1190" endedAtTime="1197" version="7.1-SNAPSHOT" parameters="231 255 291 191 259 263 207 219" wasAssociatedWith="18"/>
    <provenance:ActivityProvenance xmi:id="56" componentId="de.fraunhofer.scai.bio.uima.mysqlreader.ctgov.reader.MySQLReader" startedAtTime="1204" endedAtTime="1211" version="7.1-SNAPSHOT" parameters="187 175 199 235 211 287 303 267 275 295 215 1218 1222 195" wasAssociatedWith="20"/>
    <provenance:ActivityProvenance xmi:id="79" componentId="de.fraunhofer.scai.bio.uima.core.writer.XCasMessageWriter" startedAtTime="1226" endedAtTime="1233" version="7.1-SNAPSHOT" parameters="243 203 279 227 299 311" wasAssociatedWith="20"/>
    <provenance:ActivityProvenance xmi:id="94" componentId="de.fraunhofer.scai.bio.uima.onlp.sentencedetector.annotator.OpenNLP_SentenceDetector" startedAtTime="1240" endedAtTime="1247" version="7.1-SNAPSHOT" parameters="183 239 223 307" wasAssociatedWith="18"/>
    <provenance:ActivityProvenance xmi:id="107" componentId="de.fraunhofer.scai.bio.uima.core.writer.XCasMessageWriter" startedAtTime="1254" endedAtTime="1261" version="7.1-SNAPSHOT" parameters="283 319 247 271 315 251" wasAssociatedWith="18"/>
    <provenance:ActivityProvenance xmi:id="122" componentId="de.fraunhofer.scai.bio.uima.documentdecomposer.annotator.DocumentDecomposerAnnotator" startedAtTime="1268" endedAtTime="1275" version="7.1-SNAPSHOT" parameters="323" wasAssociatedWith="16"/>
    <provenance:ActivityProvenance xmi:id="132" componentId="de.fraunhofer.scai.bio.uima.core.writer.XCasMessageWriter" startedAtTime="1282" endedAtTime="1289" version="7.1-SNAPSHOT" parameters="327 331 335 339 343 347" wasAssociatedWith="16"/>
    <meta:Parameter xmi:id="147" key="jmsBroker" value="" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="151" key="jmsIni" value="/home/uimahpc/microservices/etc/jms.ini" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="155" key="jmsQueue" value="/queue/DocumentDecomposer.patents" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="159" key="jmsTool" value="DocumentDecomposerDeployer (7.1-SNAPSHOT)" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="163" key="documentCollectionName" value="" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="167" key="license" value="" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="171" key="recipients" value="" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="175" key="recipient" value="/queue/ONLPSentenceDetector.en;/queue/DocumentDecomposer.cune;/queue/interfacer.xmi;" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="179" key="inputString" value="" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="183" key="language" value="en" wasGeneratedBy="94"/>
    <meta:Parameter xmi:id="187" key="condition" value="false" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="191" key="jmsTool" value="OpenNLP_SentenceDetectorDeployer (7.1-SNAPSHOT)" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="195" key="event" value="" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="199" key="trackingNr" value="MDAzMGxvY2F0aW9uIHd3dy5zY2FpLmZyYXVuaG9mZXIuZGUvbXppbW1lcm1hbm4KMDAxY2lkZW50aWZpZXIgdGVzdCBsaWNlbnNlCjAwMjBjaWQgdGltZSA8IDIwNDItMDEtMDFUMDA6MDAKMDAyZnNpZ25hdHVyZSAJPOFDaQbvzzfyMuZOWHaYgFxTnpiSu3K6JZ1ys7Vp1go" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="203" key="jmsIni" value="etc/jms.ini" wasGeneratedBy="79"/>
    <meta:Parameter xmi:id="207" key="recipients" value="" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="211" key="Query" value="select * from ctgov_AlzheimerFinal where outcomeMeasureDetails is not null and id = 1463384" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="215" key="documentCollectionName" value="MZ" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="219" key="event" value="" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="223" key="doAbbrevFilter" value="false" wasGeneratedBy="94"/>
    <meta:Parameter xmi:id="227" key="jmsSource" value="/queue/dummy" wasGeneratedBy="79"/>
    <meta:Parameter xmi:id="231" key="jmsBroker" value="" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="235" key="QueryFile" value="etc/query" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="239" key="lineSeparation" value="false" wasGeneratedBy="94"/>
    <meta:Parameter xmi:id="243" key="jmsBroker" value="flux" wasGeneratedBy="79"/>
    <meta:Parameter xmi:id="247" key="jmsTool" value="OpenNLP_SentenceDetectorDeployer (7.1-SNAPSHOT)" wasGeneratedBy="107"/>
    <meta:Parameter xmi:id="251" key="storeResult" value="" wasGeneratedBy="107"/>
    <meta:Parameter xmi:id="255" key="jmsIni" value="/home/uimahpc/microservices/etc/jms.ini" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="259" key="documentCollectionName" value="" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="263" key="license" value="" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="267" key="username" value="root" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="271" key="jmsSource" value="/queue/ONLPSentenceDetector.en" wasGeneratedBy="107"/>
    <meta:Parameter xmi:id="275" key="limit" value="1" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="279" key="jmsTool" value="MysqlReaderMessageDeployer (7.1-SNAPSHOT)" wasGeneratedBy="79"/>
    <meta:Parameter xmi:id="283" key="jmsBroker" value="" wasGeneratedBy="107"/>
    <meta:Parameter xmi:id="287" key="connection" value="jdbc:mysql://flux:30008/aetionomy" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="291" key="jmsQueue" value="/queue/ONLPSentenceDetector.en" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="295" key="offset" value="0" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="299" key="jmsBilling" value="creating XCAS" wasGeneratedBy="79"/>
    <meta:Parameter xmi:id="303" key="password" value="Espe52" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="307" key="typeFilter" value="" wasGeneratedBy="94"/>
    <meta:Parameter xmi:id="311" key="storeResult" value="" wasGeneratedBy="79"/>
    <meta:Parameter xmi:id="315" key="jmsBilling" value="creating XCAS" wasGeneratedBy="107"/>
    <meta:Parameter xmi:id="319" key="jmsIni" value="/home/uimahpc/microservices/etc/jms.ini" wasGeneratedBy="107"/>
    <meta:Parameter xmi:id="323" key="sectionIniFile" value="/home/uimahpc/microservices/etc/sections-patents.ini" wasGeneratedBy="122"/>
    <meta:Parameter xmi:id="327" key="jmsBroker" value="" wasGeneratedBy="132"/>
    <meta:Parameter xmi:id="331" key="jmsIni" value="/home/uimahpc/microservices/etc/jms.ini" wasGeneratedBy="132"/>
    <meta:Parameter xmi:id="335" key="jmsTool" value="DocumentDecomposerDeployer (7.1-SNAPSHOT)" wasGeneratedBy="132"/>
    <meta:Parameter xmi:id="339" key="jmsSource" value="/queue/DocumentDecomposer.patents" wasGeneratedBy="132"/>
    <meta:Parameter xmi:id="343" key="jmsBilling" value="creating XCAS" wasGeneratedBy="132"/>
    <meta:Parameter xmi:id="347" key="storeResult" value="" wasGeneratedBy="132"/>
    <meta:KeyValue xmi:id="351" key="event" value="ExtractHeader ExtractFrontMatter"/>
    <meta:KeyValue xmi:id="355" key="entityProvenance.documentURI" value="file:/home/msood/workspace/TheInterfacer/NCT01463384"/>
    <meta:KeyValue xmi:id="359" key="tracking-nr" value="MZ"/>
    <meta:KeyValue xmi:id="363" key="license" value="MDAzMGxvY2F0aW9uIHd3dy5zY2FpLmZyYXVuaG9mZXIuZGUvbXppbW1lcm1hbm4KMDAxY2lkZW50aWZpZXIgdGVzdCBsaWNlbnNlCjAwMjBjaWQgdGltZSA8IDIwNDItMDEtMDFUMDA6MDAKMDAyZnNpZ25hdHVyZSAJPOFDaQbvzzfyMuZOWHaYgFxTnpiSu3K6JZ1ys7Vp1go"/>
    <meta:KeyValue xmi:id="367" key="unit" value="9 [DocElems],32 [Paragraphs]"/>
    <tcas:DocumentAnnotation xmi:id="371" sofa="1151" begin="0" end="10006" language="x-unspecified"/>
    <meta:Header xmi:id="376" sofa="1151" begin="0" end="0" source="Huntington Medical Research Institutes" title="Minocycline in Patients With Alzheimer's Disease" authors="1296" publicationDate="1301" ISSN="NCT01463384" documentConcept="1305"/>
    <provenance:EntityProvenance xmi:id="392" documentID="8f03a390bc5ccb56f42ba75f9373a27a70ae76a3d8e00918755bb75f2bc70da3" userSuppliedID="NCT01463384" wasDerivedFrom="http://www.scai.fraunhofer.de" workflowProvenance="56 79 39 94 107 22 122 132" wasGeneratedBy="56" wasAttributedTo="20" documentCollectionName="MZ"/>
    <tcas:DocumentAnnotation xmi:id="411" sofa="1158" begin="0" end="10006" language="x-unspecified"/>
    <meta2:DocumentTitle xmi:id="416" sofa="1158" begin="78" end="166" wasGeneratedBy="56"/>
    <meta2:Abstract xmi:id="424" sofa="1158" begin="315" end="908" wasGeneratedBy="56"/>
    <container:Section xmi:id="430" sofa="1158" begin="12" end="315" wasGeneratedBy="56" title="Overview" rhetorical="Overview"/>
    <container:Section xmi:id="439" sofa="1158" begin="329" end="2907" wasGeneratedBy="56" title="Description:" rhetorical="Description:"/>
    <container:Section xmi:id="448" sofa="1158" begin="329" end="2907" wasGeneratedBy="56" title="Detailed Description:" rhetorical="Detailed Description:"/>
    <container:Section xmi:id="457" sofa="1158" begin="930" end="2907" wasGeneratedBy="56" title="Brief Summary:" rhetorical="Brief Summary:"/>
    <container:Section xmi:id="466" sofa="1158" begin="2916" end="3720" wasGeneratedBy="56" title="Criteria:" rhetorical="Criteria:"/>
    <container:Section xmi:id="475" sofa="1158" begin="3735" end="4094" wasGeneratedBy="56" title="Further Study Details:" rhetorical="Further Study Details:"/>
    <container:SubSection xmi:id="484" sofa="1158" begin="909" end="10006" wasGeneratedBy="122" title="DETAILS"/>
    <container:SubSection xmi:id="493" sofa="1158" begin="2936" end="3118" wasGeneratedBy="56" title="Inclusion Criteria." rhetorical="Inclusion Criteria."/>
    <container:SubSection xmi:id="502" sofa="1158" begin="3137" end="3720" wasGeneratedBy="56" title="Exclusion Criteria." rhetorical="Exclusion Criteria."/>
    <structure:List xmi:id="511" sofa="1158" begin="4091" end="9958" wasGeneratedBy="56" rhetorical="Additional Information:">
        <items>1. Design Information:</items>
        <items>1.1 Design Name: Endpoint Classification,Design Value: Efficacy Study Design Name: Intervention Model,Design Value: Single Group Assignment Design Name: Masking,Design Value: Open Label Design Name: Primary Purpose,Design Value: Treatment</items>
        <items>2. Intervention Information:</items>
        <items>2.1 Intervention Type: Drug,Intervention Name: Minocycline,Intervention Description: 50mg, twice daily for 6 months.</items>
        <items>3. Outcome Details:</items>
        <items>3.1 Outcome Details: Outcome Type: Primary,Outcome Title: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS),Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged),Outcome Description: RBANS is a brief neurocognitive battery with four alternate forms, measuring immediate and delayed memory, attention, language, and visuospatial skills. RBANS was developed as a stand-alone ???core??? battery for the detection and neurocognitive characterization of dementia and as a brief neurocognitive battery for the detection and tracking of neurocognitive deficits in a variety of disorders. (Reference: http://rbans.com/) Qualitative Description of Index Scores: Index Score Classification 130 and above Very Superior 120-129 Superior 110-119 High Average 90-109 Average 80-89 Low Average 70-79 Borderline 69 and below Extremely Low Psychometric range for RBANS: AD 0 - 77 MCI 78 - 99 Normal &gt; 100 Range of scores: Minimum = 0, Maximum = 130 Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. Outcome Type: Primary,Outcome Title: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).,Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged),Outcome Description: Using magnetic resonance images acquired, hippocampal volume was measured monthly for 6 months. Normal range for hippocampal volume in aged-matched controls is 6.6 - 8.8 cm^3. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. Outcome Type: Primary,Outcome Title: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC),Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged),Outcome Description: It has been demonstrated in numerous studies over the past decade that magnetic resonance spectroscopy (MRS) can be used for the diagnosis of Alzheimer???s disease. By measuring an area within the posterior cingulate gyrus, one can obtain a biochemical signature of that region in AD whereby NAA is reduced and mI is increased. These two biomarkers, N-acetylaspartate (NAA, a neuronal marker) and myo-inositol (mI, a glial marker) were quantified and then used to calculate NAA/mI (an index currently widely used for AD and MCI diagnosis). Scale of MRS biomarkers for aged-matched controls: NAA = 1.43, mI = 0.60, NAA/mI = 2.38. Any value lower than NAA/mI of 2.38 are considered not normal. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration.</items>
        <items>3.2 Outcome Analysis Details: No information</items>
        <items>3.3 Outcome Measure Details: Outcome Units of Measure:Ratio,Measure Type: Mean Outcome Units of Measure:cm^3,Measure Type: Mean Outcome Units of Measure:units on a scale,Measure Type: Mean Outcome Units of Measure:participants,Measure Type: Number</items>
        <items>3.4 Outcome Values: 1,8,4,32.5,32.9,81,58.7,63.8,106,108.4,123.6,49,5.49,5.42,4.94,6.35,6.30,7.60,6.98,6.92,6.82,2.44,2.47,1.69,1.78,1.84,1.87,1.80,2.08,2.42</items>
        <items>4. Study Outcome Details:</items>
        <items>4.1 Study Outcome Type: primary outcome,Measure: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Study Outcome Type: primary outcome,Measure: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC). Study Outcome Type: primary outcome,Measure: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)</items>
        <items>5. Location Details:</items>
        <items>5.1 Facility Details: City: Pasadena,Country: United States,Facility Name: Huntington Medical Research Institutes</items>
        <items>5.2 Facility Contact Details: No information</items>
        <items>6. Responsible Party Details:</items>
        <items>6.1 No information</items>
        <items>7. Arm Group Details;</items>
        <items>7.1 Arm Group Label: Minocycline,Arm Group Type: Active Comparator,Arm Group DEscription: Subjects will be administered 50mg minocycline twice daily. Arm Group Label: Minocycline,Arm Group Type: Baseline,Arm Group DEscription: Subjects administered 50mg minocycline twice daily for 6 months Arm Group Label: Minocycline,Arm Group Type: Participant Flow,Arm Group DEscription: Subjects were administered 50mg minocycline twice daily for 6 months Arm Group Label: Minocycline MCI,Arm Group Type: Results Outcome,Arm Group DEscription: Mild cognitively impaired subject who was administered 50mg minocycline twice daily. Arm Group Label: Minocycline AD,Arm Group Type: Results Outcome,Arm Group DEscription: Alzheimer subjects who were administered 50mg minocycline twice daily. Arm Group Label: Minocycline NC,Arm Group Type: Results Outcome,Arm Group DEscription: Normal control subjects who were administered 50mg minocycline twice daily.</items>
        <items>8. Baseline Measure Details:</items>
        <items>8.1 Baseline ID:	13745</items>
        <items>8.2 Baseline Measure Details:	No information</items>
        <items>8.3 Baseline Measure Cateogary Details:	Cateogary Title: Female,Baseline Value: 308 Cateogary Title: Male,Baseline Value: 433 Cateogary Title: Female,Baseline Value: 178 Cateogary Title: Male,Baseline Value: 191 Cateogary Title: Female,Baseline Value: 190 Cateogary Title: Female,Baseline Value: 676 Cateogary Title: Male,Baseline Value: 815</items>
        <items>9. Reference:</items>
    </structure:List>
    <meta2:Reference xmi:id="589" sofa="1158" begin="3801" end="3815" wasGeneratedBy="56"/>
    <text:NamedEntity xmi:id="600" sofa="1158" begin="2686" end="2694" wasGeneratedBy="1314"/>
    <text:Sentence xmi:id="607" sofa="1158" begin="0" end="642" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="614" sofa="1158" begin="643" end="796" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="621" sofa="1158" begin="797" end="908" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="628" sofa="1158" begin="909" end="1388" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="635" sofa="1158" begin="1389" end="1711" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="642" sofa="1158" begin="1712" end="1875" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="649" sofa="1158" begin="1876" end="2080" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="656" sofa="1158" begin="2081" end="2195" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="663" sofa="1158" begin="2196" end="2316" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="670" sofa="1158" begin="2317" end="2483" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="677" sofa="1158" begin="2484" end="2657" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="684" sofa="1158" begin="2658" end="2906" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="691" sofa="1158" begin="2907" end="2936" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="698" sofa="1158" begin="2938" end="3117" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="705" sofa="1158" begin="3118" end="3137" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="712" sofa="1158" begin="3139" end="3281" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="719" sofa="1158" begin="3283" end="3421" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="726" sofa="1158" begin="3423" end="3719" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="733" sofa="1158" begin="3720" end="4521" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="740" sofa="1158" begin="4523" end="4937" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="747" sofa="1158" begin="4938" end="5182" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="754" sofa="1158" begin="5183" end="5213" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="761" sofa="1158" begin="5214" end="5661" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="768" sofa="1158" begin="5662" end="5844" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="775" sofa="1158" begin="5845" end="6044" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="782" sofa="1158" begin="6045" end="6124" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="789" sofa="1158" begin="6125" end="6252" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="796" sofa="1158" begin="6253" end="6700" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="803" sofa="1158" begin="6701" end="6863" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="810" sofa="1158" begin="6864" end="7075" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="817" sofa="1158" begin="7076" end="7164" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="824" sofa="1158" begin="7165" end="7227" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="831" sofa="1158" begin="7228" end="7355" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="838" sofa="1158" begin="7356" end="8144" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="845" sofa="1158" begin="8145" end="8512" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="852" sofa="1158" begin="8513" end="8733" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="859" sofa="1158" begin="8734" end="9201" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="866" sofa="1158" begin="9202" end="9359" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="873" sofa="1158" begin="9360" end="9522" wasGeneratedBy="94"/>
    <text:Sentence xmi:id="880" sofa="1158" begin="9524" end="10006" wasGeneratedBy="94"/>
    <structure:Paragraph xmi:id="887" sofa="1158" begin="3816" end="3861" wasGeneratedBy="122" rhetorical="par_1"/>
    <structure:Paragraph xmi:id="894" sofa="1158" begin="3862" end="3876" wasGeneratedBy="122" rhetorical="par_2"/>
    <structure:Paragraph xmi:id="901" sofa="1158" begin="3877" end="3889" wasGeneratedBy="122" rhetorical="par_3"/>
    <structure:Paragraph xmi:id="908" sofa="1158" begin="3890" end="3911" wasGeneratedBy="122" rhetorical="par_4"/>
    <structure:Paragraph xmi:id="915" sofa="1158" begin="3912" end="3933" wasGeneratedBy="122" rhetorical="par_5"/>
    <structure:Paragraph xmi:id="922" sofa="1158" begin="3935" end="4000" wasGeneratedBy="122" rhetorical="par_6"/>
    <structure:Paragraph xmi:id="929" sofa="1158" begin="4001" end="4064" wasGeneratedBy="122" rhetorical="par_7"/>
    <structure:Paragraph xmi:id="936" sofa="1158" begin="4065" end="4089" wasGeneratedBy="122" rhetorical="par_8"/>
    <structure:Paragraph xmi:id="943" sofa="1158" begin="4091" end="4113" wasGeneratedBy="122" rhetorical="par_9"/>
    <structure:Paragraph xmi:id="950" sofa="1158" begin="4114" end="4353" wasGeneratedBy="122" rhetorical="par_10"/>
    <structure:Paragraph xmi:id="957" sofa="1158" begin="4355" end="4383" wasGeneratedBy="122" rhetorical="par_11"/>
    <structure:Paragraph xmi:id="964" sofa="1158" begin="4384" end="4521" wasGeneratedBy="122" rhetorical="par_12"/>
    <structure:Paragraph xmi:id="971" sofa="1158" begin="4523" end="4542" wasGeneratedBy="122" rhetorical="par_13"/>
    <structure:Paragraph xmi:id="978" sofa="1158" begin="4543" end="7355" wasGeneratedBy="122" rhetorical="par_14"/>
    <structure:Paragraph xmi:id="985" sofa="1158" begin="7356" end="7400" wasGeneratedBy="122" rhetorical="par_15"/>
    <structure:Paragraph xmi:id="992" sofa="1158" begin="7401" end="7648" wasGeneratedBy="122" rhetorical="par_16"/>
    <structure:Paragraph xmi:id="999" sofa="1158" begin="7649" end="7806" wasGeneratedBy="122" rhetorical="par_17"/>
    <structure:Paragraph xmi:id="1006" sofa="1158" begin="7808" end="7833" wasGeneratedBy="122" rhetorical="par_18"/>
    <structure:Paragraph xmi:id="1013" sofa="1158" begin="7834" end="8326" wasGeneratedBy="122" rhetorical="par_19"/>
    <structure:Paragraph xmi:id="1020" sofa="1158" begin="8328" end="8348" wasGeneratedBy="122" rhetorical="par_20"/>
    <structure:Paragraph xmi:id="1027" sofa="1158" begin="8349" end="8462" wasGeneratedBy="122" rhetorical="par_21"/>
    <structure:Paragraph xmi:id="1034" sofa="1158" begin="8464" end="8508" wasGeneratedBy="122" rhetorical="par_22"/>
    <structure:Paragraph xmi:id="1041" sofa="1158" begin="8510" end="8539" wasGeneratedBy="122" rhetorical="par_23"/>
    <structure:Paragraph xmi:id="1048" sofa="1158" begin="8540" end="8559" wasGeneratedBy="122" rhetorical="par_24"/>
    <structure:Paragraph xmi:id="1055" sofa="1158" begin="8561" end="8582" wasGeneratedBy="122" rhetorical="par_25"/>
    <structure:Paragraph xmi:id="1062" sofa="1158" begin="8583" end="9522" wasGeneratedBy="122" rhetorical="par_26"/>
    <structure:Paragraph xmi:id="1069" sofa="1158" begin="9524" end="9552" wasGeneratedBy="122" rhetorical="par_27"/>
    <structure:Paragraph xmi:id="1076" sofa="1158" begin="9553" end="9575" wasGeneratedBy="122" rhetorical="par_28"/>
    <structure:Paragraph xmi:id="1083" sofa="1158" begin="9576" end="9620" wasGeneratedBy="122" rhetorical="par_29"/>
    <structure:Paragraph xmi:id="1090" sofa="1158" begin="9621" end="9962" wasGeneratedBy="122" rhetorical="par_30"/>
    <structure:Paragraph xmi:id="1097" sofa="1158" begin="9964" end="9977" wasGeneratedBy="122" rhetorical="par_31"/>
    <structure:Paragraph xmi:id="1104" sofa="1158" begin="9978" end="10005" wasGeneratedBy="122" rhetorical="par_32"/>
    <meta2:TableOfContents xmi:id="1111" sofa="1158" begin="10004" end="10005" wasGeneratedBy="122" outlines="430 439 448 484 457 466 493 502 475"/>
    <tcas:DocumentAnnotation xmi:id="1146" sofa="1165" begin="0" end="3422" language="x-unspecified"/>
    <cas:Sofa xmi:id="1151" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="Brief Title:&#9;Minocycline in Patients With Alzheimer's Disease&#10;Official Title:&#9;MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy&#10;NCT-ID:&#9;NCT01463384&#10;Start Date:&#9;September 2011&#10;Completion Date:&#9;October 2012&#10;First Received Date:&#9;October 25, 2011&#10;Last Updated:&#9;September 23, 2014&#10;Brief Summary:&#10;Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance imaging (MRI) and proton (1H ) and carbon 13 (13C) magnetic resonance spectroscopy (MRS). Each individual will receive minocycline oral administration for 4 weeks initially, after which MRI, MRS and neuropsychological results will be recorded. If no adverse side effects occur, subjects will continue minocycline administration for an additional 5 months.&#10;Detailed Description:&#10;In the course of on-going trials of novel MRI procedures for Neurological Diagnosis, the investigators have established non-invasive BIOMARKERS (Note: Biomarkers are objective Laboratory tests used in, but not replacing Clinical diagnostic criteria of any disease,in this case age-related dementia of the Alzheimer type and its pre-clinical forms including Mild Cognitive Impairment - MCI) which significantly assist in the Diagnosis of Alzheimer's Disease. MRS, rather like blood tests which are applied for screening and exclusion of medical disorders, provides a pattern of brain chemicals from which this and many other diagnoses have become available (see: Magnetic Resonance Spectroscopy in Neurological Diagnosis: E.R Danielsen and B.D. Ross, Marcel Dekker New York, 1999). Diagnosis of Alzheimer's Disease has hitherto been exclusively a clinical diagnosis, made on the basis of non-specific tests by the treating physician/neurologist. Furthermore, treatments have been of limited efficacy so that the pressure for conclusive diagnosis or an objective characterization of disease progression (or better, regression) has not been a priority. This conservative approach to Alzheimer's Disease changed in 2010 with the Report of National Institutes of Aging. First: The failures of treatment have been ascribed to introduction only in patients with advanced disease (&quot;dementia&quot;). Second: A preliminary form of AD, known as pre-clinical or Mild Cognitive Impairment, has been recognized, distinct from, and generally earlier in the disease course. Third: A new set of diagnostic criteria, which include objective 'biomarkers', from cerebrospinal fluid, genetic and imaging analyzes, has been accepted by the Expert Panel. Finally, Clinical trials of existing and new drugs for Alzheimer's Disease are expected to yield better results if initiated earlier - in the pre-clinical phase - and the outcomes evaluated by the earlier changes in an approved panel of biomarkers.&#10;Criteria:&#10;Inclusion Criteria.&#10; - Cognitively normal elderly subjects between the ages of 55-90 and patients aged 55 - 90 years who have mild cognitive impairment (MCI) or clinically defined Alzheimer's disease. Exclusion Criteria.&#10; - Any person with medical devices such as cardiac pacemakers/defibrillators or neuro-implants as they are contra-indications for MRI/MRS exam.&#10; - Since the effects of MRI are unknown to the fetus or unborn child, any person who is or may be pregnant will be excluded from the study.&#10; - History of known allergy or intolerance to minocycline or any other tetracycline - Impaired renal function (plasma Creatinine) or blood urea nitrogen (BUN) levels exceeds twice normal upper limit which can result in higher serum levels of tetracycline, azotemia, hyperphosphatemia and acidosis.&#10;Overall Status:&#9;Completed&#10;Phase:&#9;Phase 2&#10;Study Type:&#9;Interventional&#10;Why Stopped:&#9;No information&#10;Healthy Volunteer:&#9;Accepts Healthy Volunteers&#10;Enrollment:&#9;13&#10;Gender:&#9;Both&#10;Minimum Age:&#9;55 Years&#10;Maximum Age:&#9;90 Years&#10;&#10;Disease Condition:&#9;Mild Cognitive Impairment;;Alzheimer's Disease&#10;Other ID's:&#9;Secondary ID: No information,Org Study ID: LKW-AB34&#10;PubMedID:&#9;No information&#10;&#10;1. Design Information:&#10;1.1 &#9;Design Name: Endpoint Classification,Design Value: Efficacy Study Design Name: Intervention Model,Design Value: Single Group Assignment Design Name: Masking,Design Value: Open Label Design Name: Primary Purpose,Design Value: Treatment&#10;&#10;2. Intervention Information:&#10;2.1 Intervention Details&#9;Intervention Type: Drug,Intervention Name: Minocycline,Intervention Description: 50mg, twice daily for 6 months.&#10;&#10;3. Outcome Details:&#10;3.1 Outcome Details:&#9;Outcome Type: Primary,Outcome Title: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS),Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged),Outcome Description: RBANS is a brief neurocognitive battery with four alternate forms, measuring immediate and delayed memory, attention, language, and visuospatial skills. RBANS was developed as a stand-alone ???core??? battery for the detection and neurocognitive characterization of dementia and as a brief neurocognitive battery for the detection and tracking of neurocognitive deficits in a variety of disorders. (Reference: http://rbans.com/) Qualitative Description of Index Scores: Index Score Classification 130 and above Very Superior 120-129 Superior 110-119 High Average 90-109 Average 80-89 Low Average 70-79 Borderline 69 and below Extremely Low Psychometric range for RBANS: AD 0 - 77 MCI 78 - 99 Normal &gt; 100 Range of scores: Minimum = 0, Maximum = 130 Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. Outcome Type: Primary,Outcome Title: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).,Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged),Outcome Description: Using magnetic resonance images acquired, hippocampal volume was measured monthly for 6 months. Normal range for hippocampal volume in aged-matched controls is 6.6 - 8.8 cm^3. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. Outcome Type: Primary,Outcome Title: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC),Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged),Outcome Description: It has been demonstrated in numerous studies over the past decade that magnetic resonance spectroscopy (MRS) can be used for the diagnosis of Alzheimer???s disease. By measuring an area within the posterior cingulate gyrus, one can obtain a biochemical signature of that region in AD whereby NAA is reduced and mI is increased. These two biomarkers, N-acetylaspartate (NAA, a neuronal marker) and myo-inositol (mI, a glial marker) were quantified and then used to calculate NAA/mI (an index currently widely used for AD and MCI diagnosis). Scale of MRS biomarkers for aged-matched controls: NAA = 1.43, mI = 0.60, NAA/mI = 2.38. Any value lower than NAA/mI of 2.38 are considered not normal. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration.&#10;3.2 Outcome Analysis Details:&#9;No information&#10;3.3 Outcome Measure Details:&#9;Outcome Units of Measure:Ratio,Measure Type: Mean Outcome Units of Measure:cm^3,Measure Type: Mean Outcome Units of Measure:units on a scale,Measure Type: Mean Outcome Units of Measure:participants,Measure Type: Number&#10;3.4 Outcome Values:&#9;1,8,4,32.5,32.9,81,58.7,63.8,106,108.4,123.6,49,5.49,5.42,4.94,6.35,6.30,7.60,6.98,6.92,6.82,2.44,2.47,1.69,1.78,1.84,1.87,1.80,2.08,2.42&#10;&#10;4. Study Outcome Details:&#10;4.1 &#9;Study Outcome Type: primary outcome,Measure: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Study Outcome Type: primary outcome,Measure: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC). Study Outcome Type: primary outcome,Measure: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)&#10;&#10;5. Location Details:&#10;5.1 Facility Details:&#9;City: Pasadena,Country: United States,Facility Name: Huntington Medical Research Institutes&#10;&#10;5.2 Facility Contact Details:&#9;No information&#10;&#10;6. Responsible Party Details:&#10;6.1 &#9;No information&#10;&#10;7. Arm Group Details;&#10;7.1 &#9;Arm Group Label: Minocycline,Arm Group Type: Active Comparator,Arm Group DEscription: Subjects will be administered 50mg minocycline twice daily. Arm Group Label: Minocycline,Arm Group Type: Baseline,Arm Group DEscription: Subjects administered 50mg minocycline twice daily for 6 months Arm Group Label: Minocycline,Arm Group Type: Participant Flow,Arm Group DEscription: Subjects were administered 50mg minocycline twice daily for 6 months Arm Group Label: Minocycline MCI,Arm Group Type: Results Outcome,Arm Group DEscription: Mild cognitively impaired subject who was administered 50mg minocycline twice daily. Arm Group Label: Minocycline AD,Arm Group Type: Results Outcome,Arm Group DEscription: Alzheimer subjects who were administered 50mg minocycline twice daily. Arm Group Label: Minocycline NC,Arm Group Type: Results Outcome,Arm Group DEscription: Normal control subjects who were administered 50mg minocycline twice daily.&#10;&#10;8. Baseline Measure Details:&#10;8.1 Baseline ID:&#9;13745&#10;8.2 Baseline Measure Details:&#9;No information&#10;8.3 Baseline Measure Cateogary Details:&#9;Cateogary Title: Female,Baseline Value: 308 Cateogary Title: Male,Baseline Value: 433 Cateogary Title: Female,Baseline Value: 178 Cateogary Title: Male,Baseline Value: 191 Cateogary Title: Female,Baseline Value: 190 Cateogary Title: Female,Baseline Value: 676 Cateogary Title: Male,Baseline Value: 815&#10;&#10;9. Reference:&#10;9.1 Citation&#9;No information&#10;"/>
    <cas:Sofa xmi:id="1158" sofaNum="2" sofaID="DocumentView" mimeType="text" sofaString="Brief Title:&#9;Minocycline in Patients With Alzheimer's Disease&#10;Official Title:&#9;MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy&#10;NCT-ID:&#9;NCT01463384&#10;Start Date:&#9;September 2011&#10;Completion Date:&#9;October 2012&#10;First Received Date:&#9;October 25, 2011&#10;Last Updated:&#9;September 23, 2014&#10;Brief Summary:&#10;Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance imaging (MRI) and proton (1H ) and carbon 13 (13C) magnetic resonance spectroscopy (MRS). Each individual will receive minocycline oral administration for 4 weeks initially, after which MRI, MRS and neuropsychological results will be recorded. If no adverse side effects occur, subjects will continue minocycline administration for an additional 5 months.&#10;Detailed Description:&#10;In the course of on-going trials of novel MRI procedures for Neurological Diagnosis, the investigators have established non-invasive BIOMARKERS (Note: Biomarkers are objective Laboratory tests used in, but not replacing Clinical diagnostic criteria of any disease,in this case age-related dementia of the Alzheimer type and its pre-clinical forms including Mild Cognitive Impairment - MCI) which significantly assist in the Diagnosis of Alzheimer's Disease. MRS, rather like blood tests which are applied for screening and exclusion of medical disorders, provides a pattern of brain chemicals from which this and many other diagnoses have become available (see: Magnetic Resonance Spectroscopy in Neurological Diagnosis: E.R Danielsen and B.D. Ross, Marcel Dekker New York, 1999). Diagnosis of Alzheimer's Disease has hitherto been exclusively a clinical diagnosis, made on the basis of non-specific tests by the treating physician/neurologist. Furthermore, treatments have been of limited efficacy so that the pressure for conclusive diagnosis or an objective characterization of disease progression (or better, regression) has not been a priority. This conservative approach to Alzheimer's Disease changed in 2010 with the Report of National Institutes of Aging. First: The failures of treatment have been ascribed to introduction only in patients with advanced disease (&quot;dementia&quot;). Second: A preliminary form of AD, known as pre-clinical or Mild Cognitive Impairment, has been recognized, distinct from, and generally earlier in the disease course. Third: A new set of diagnostic criteria, which include objective 'biomarkers', from cerebrospinal fluid, genetic and imaging analyzes, has been accepted by the Expert Panel. Finally, Clinical trials of existing and new drugs for Alzheimer's Disease are expected to yield better results if initiated earlier - in the pre-clinical phase - and the outcomes evaluated by the earlier changes in an approved panel of biomarkers.&#10;Criteria:&#10;Inclusion Criteria.&#10; - Cognitively normal elderly subjects between the ages of 55-90 and patients aged 55 - 90 years who have mild cognitive impairment (MCI) or clinically defined Alzheimer's disease. Exclusion Criteria.&#10; - Any person with medical devices such as cardiac pacemakers/defibrillators or neuro-implants as they are contra-indications for MRI/MRS exam.&#10; - Since the effects of MRI are unknown to the fetus or unborn child, any person who is or may be pregnant will be excluded from the study.&#10; - History of known allergy or intolerance to minocycline or any other tetracycline - Impaired renal function (plasma Creatinine) or blood urea nitrogen (BUN) levels exceeds twice normal upper limit which can result in higher serum levels of tetracycline, azotemia, hyperphosphatemia and acidosis.&#10;Overall Status:&#9;Completed&#10;Phase:&#9;Phase 2&#10;Study Type:&#9;Interventional&#10;Why Stopped:&#9;No information&#10;Healthy Volunteer:&#9;Accepts Healthy Volunteers&#10;Enrollment:&#9;13&#10;Gender:&#9;Both&#10;Minimum Age:&#9;55 Years&#10;Maximum Age:&#9;90 Years&#10;&#10;Disease Condition:&#9;Mild Cognitive Impairment;;Alzheimer's Disease&#10;Other ID's:&#9;Secondary ID: No information,Org Study ID: LKW-AB34&#10;PubMedID:&#9;No information&#10;&#10;1. Design Information:&#10;1.1 &#9;Design Name: Endpoint Classification,Design Value: Efficacy Study Design Name: Intervention Model,Design Value: Single Group Assignment Design Name: Masking,Design Value: Open Label Design Name: Primary Purpose,Design Value: Treatment&#10;&#10;2. Intervention Information:&#10;2.1 Intervention Details&#9;Intervention Type: Drug,Intervention Name: Minocycline,Intervention Description: 50mg, twice daily for 6 months.&#10;&#10;3. Outcome Details:&#10;3.1 Outcome Details:&#9;Outcome Type: Primary,Outcome Title: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS),Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged),Outcome Description: RBANS is a brief neurocognitive battery with four alternate forms, measuring immediate and delayed memory, attention, language, and visuospatial skills. RBANS was developed as a stand-alone ???core??? battery for the detection and neurocognitive characterization of dementia and as a brief neurocognitive battery for the detection and tracking of neurocognitive deficits in a variety of disorders. (Reference: http://rbans.com/) Qualitative Description of Index Scores: Index Score Classification 130 and above Very Superior 120-129 Superior 110-119 High Average 90-109 Average 80-89 Low Average 70-79 Borderline 69 and below Extremely Low Psychometric range for RBANS: AD 0 - 77 MCI 78 - 99 Normal &gt; 100 Range of scores: Minimum = 0, Maximum = 130 Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. Outcome Type: Primary,Outcome Title: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).,Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged),Outcome Description: Using magnetic resonance images acquired, hippocampal volume was measured monthly for 6 months. Normal range for hippocampal volume in aged-matched controls is 6.6 - 8.8 cm^3. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. Outcome Type: Primary,Outcome Title: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC),Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged),Outcome Description: It has been demonstrated in numerous studies over the past decade that magnetic resonance spectroscopy (MRS) can be used for the diagnosis of Alzheimer???s disease. By measuring an area within the posterior cingulate gyrus, one can obtain a biochemical signature of that region in AD whereby NAA is reduced and mI is increased. These two biomarkers, N-acetylaspartate (NAA, a neuronal marker) and myo-inositol (mI, a glial marker) were quantified and then used to calculate NAA/mI (an index currently widely used for AD and MCI diagnosis). Scale of MRS biomarkers for aged-matched controls: NAA = 1.43, mI = 0.60, NAA/mI = 2.38. Any value lower than NAA/mI of 2.38 are considered not normal. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration.&#10;3.2 Outcome Analysis Details:&#9;No information&#10;3.3 Outcome Measure Details:&#9;Outcome Units of Measure:Ratio,Measure Type: Mean Outcome Units of Measure:cm^3,Measure Type: Mean Outcome Units of Measure:units on a scale,Measure Type: Mean Outcome Units of Measure:participants,Measure Type: Number&#10;3.4 Outcome Values:&#9;1,8,4,32.5,32.9,81,58.7,63.8,106,108.4,123.6,49,5.49,5.42,4.94,6.35,6.30,7.60,6.98,6.92,6.82,2.44,2.47,1.69,1.78,1.84,1.87,1.80,2.08,2.42&#10;&#10;4. Study Outcome Details:&#10;4.1 &#9;Study Outcome Type: primary outcome,Measure: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Study Outcome Type: primary outcome,Measure: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC). Study Outcome Type: primary outcome,Measure: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)&#10;&#10;5. Location Details:&#10;5.1 Facility Details:&#9;City: Pasadena,Country: United States,Facility Name: Huntington Medical Research Institutes&#10;&#10;5.2 Facility Contact Details:&#9;No information&#10;&#10;6. Responsible Party Details:&#10;6.1 &#9;No information&#10;&#10;7. Arm Group Details;&#10;7.1 &#9;Arm Group Label: Minocycline,Arm Group Type: Active Comparator,Arm Group DEscription: Subjects will be administered 50mg minocycline twice daily. Arm Group Label: Minocycline,Arm Group Type: Baseline,Arm Group DEscription: Subjects administered 50mg minocycline twice daily for 6 months Arm Group Label: Minocycline,Arm Group Type: Participant Flow,Arm Group DEscription: Subjects were administered 50mg minocycline twice daily for 6 months Arm Group Label: Minocycline MCI,Arm Group Type: Results Outcome,Arm Group DEscription: Mild cognitively impaired subject who was administered 50mg minocycline twice daily. Arm Group Label: Minocycline AD,Arm Group Type: Results Outcome,Arm Group DEscription: Alzheimer subjects who were administered 50mg minocycline twice daily. Arm Group Label: Minocycline NC,Arm Group Type: Results Outcome,Arm Group DEscription: Normal control subjects who were administered 50mg minocycline twice daily.&#10;&#10;8. Baseline Measure Details:&#10;8.1 Baseline ID:&#9;13745&#10;8.2 Baseline Measure Details:&#9;No information&#10;8.3 Baseline Measure Cateogary Details:&#9;Cateogary Title: Female,Baseline Value: 308 Cateogary Title: Male,Baseline Value: 433 Cateogary Title: Female,Baseline Value: 178 Cateogary Title: Male,Baseline Value: 191 Cateogary Title: Female,Baseline Value: 190 Cateogary Title: Female,Baseline Value: 676 Cateogary Title: Male,Baseline Value: 815&#10;&#10;9. Reference:&#10;9.1 Citation&#9;No information&#10;"/>
    <cas:Sofa xmi:id="1165" sofaNum="3" sofaID="ContentView" mimeType="text" sofaString="Table of Contents:&#10;    Overview &#9;Minocycline in _______________________________________________ 12 &#10;    Description:  _________________________________________________________ 329 &#10;    Detailed Description:  ________________________________________________ 329 &#10;      DETAILS Detailed Descri _____________________________________________ 909 &#10;    Brief Summary:  _______________________________________________________ 930 &#10;    Criteria:  ___________________________________________________________ 2916 &#10;      Inclusion Criteria.  _______________________________________________ 2936 &#10;      Exclusion Criteria.  _______________________________________________ 3137 &#10;    Further Study Details: &#9;Completed ____________________________________ 3735 &#10;&#10;    par_1: Healthy Volunte _______________________________________________ 3816 &#10;    par_2: Enrollment:&#9;13 ________________________________________________ 3862 &#10;    par_3: Gender:&#9;Both __________________________________________________ 3877 &#10;    par_4: Minimum Age:&#9;55 _______________________________________________ 3890 &#10;    par_5: Maximum Age:&#9;90 _______________________________________________ 3912 &#10;    par_6: Disease Conditi _______________________________________________ 3935 &#10;    par_7: Other ID's:&#9;Sec _______________________________________________ 4001 &#10;    par_8: PubMedID:&#9;No in _______________________________________________ 4065 &#10;    Additional Information:: 1. Design Infor _____________________________ 4091 &#10;    par_9: 1. Design Infor _______________________________________________ 4091 &#10;    par_10: 1.1 &#9;Design Nam ______________________________________________ 4114 &#10;    par_11: 2. Intervention ______________________________________________ 4355 &#10;    par_12: 2.1 Interventio ______________________________________________ 4384 &#10;    par_13: 3. Outcome Deta ______________________________________________ 4523 &#10;    par_14: 3.1 Outcome Det ______________________________________________ 4543 &#10;    par_15: 3.2 Outcome Ana ______________________________________________ 7356 &#10;    par_16: 3.3 Outcome Mea ______________________________________________ 7401 &#10;    par_17: 3.4 Outcome Val ______________________________________________ 7649 &#10;    par_18: 4. Study Outcom ______________________________________________ 7808 &#10;    par_19: 4.1 &#9;Study Outc ______________________________________________ 7834 &#10;    par_20: 5. Location Det ______________________________________________ 8328 &#10;    par_21: 5.1 Facility De ______________________________________________ 8349 &#10;    par_22: 5.2 Facility Co ______________________________________________ 8464 &#10;    par_23: 6. Responsible  ______________________________________________ 8510 &#10;    par_24: 6.1 &#9;No informa ______________________________________________ 8540 &#10;    par_25: 7. Arm Group De ______________________________________________ 8561 &#10;    par_26: 7.1 &#9;Arm Group  ______________________________________________ 8583 &#10;    par_27: 8. Baseline Mea ______________________________________________ 9524 &#10;    par_28: 8.1 Baseline ID ______________________________________________ 9553 &#10;    par_29: 8.2 Baseline Me ______________________________________________ 9576 &#10;    par_30: 8.3 Baseline Me ______________________________________________ 9621 &#10;    par_31: 9. Reference: ________________________________________________ 9964 &#10;    par_32: 9.1 Citation&#9;No ______________________________________________ 9978 &#10;"/>
    <meta:DateTime xmi:id="1172" day="22" month="5" year="2016" hour="13" minute="44" second="33"/>
    <meta:DateTime xmi:id="1179" day="22" month="5" year="2016" hour="13" minute="54" second="7"/>
    <meta:Parameter xmi:id="1186" key="event" value="ExtractHeader ExtractFrontMatter" wasGeneratedBy="22"/>
    <meta:DateTime xmi:id="1190" day="22" month="5" year="2016" hour="13" minute="44" second="33"/>
    <meta:DateTime xmi:id="1197" day="22" month="5" year="2016" hour="13" minute="54" second="7"/>
    <meta:DateTime xmi:id="1204" day="20" month="5" year="2016" hour="10" minute="54" second="10"/>
    <meta:DateTime xmi:id="1211" day="20" month="5" year="2016" hour="10" minute="54" second="10"/>
    <meta:Parameter xmi:id="1218" key="license" value="" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="1222" key="recipients" value="" wasGeneratedBy="56"/>
    <meta:DateTime xmi:id="1226" day="20" month="5" year="2016" hour="10" minute="54" second="10"/>
    <meta:DateTime xmi:id="1233" day="20" month="5" year="2016" hour="10" minute="54" second="10"/>
    <meta:DateTime xmi:id="1240" day="22" month="5" year="2016" hour="13" minute="54" second="7"/>
    <meta:DateTime xmi:id="1247" day="22" month="5" year="2016" hour="13" minute="54" second="7"/>
    <meta:DateTime xmi:id="1254" day="22" month="5" year="2016" hour="13" minute="54" second="7"/>
    <meta:DateTime xmi:id="1261" day="22" month="5" year="2016" hour="13" minute="54" second="7"/>
    <meta:DateTime xmi:id="1268" day="22" month="5" year="2016" hour="13" minute="54" second="7"/>
    <meta:DateTime xmi:id="1275" day="22" month="5" year="2016" hour="13" minute="54" second="7"/>
    <meta:DateTime xmi:id="1282" day="22" month="5" year="2016" hour="13" minute="54" second="7"/>
    <meta:DateTime xmi:id="1289" day="22" month="5" year="2016" hour="13" minute="54" second="7"/>
    <meta:Person xmi:id="1296" surname="" forename=""/>
    <meta:Date xmi:id="1301" day="25" month="10" year="2011"/>
    <meta:Concept xmi:id="1305" prefLabel="1311" identifier="NCT01463384" identifierSource="clinicaltrials.gov"/>
    <meta:Label xmi:id="1311" value="ctgov:NCT01463384"/>
    <provenance:ActivityProvenance xmi:id="1314" componentId="Manual Annotation 1" startedAtTime="1337" endedAtTime="1337" version="7.1-SNAPSHOT" parameters="187 175 199 235 211 287 303 267 275 295 215 1218 1222 195" wasAssociatedWith="20"/>
    <meta:DateTime xmi:id="1337" day="20" month="2" year="1" hour="10" minute="12" second="0"/>
    <cas:View sofa="1151" members="1 6 11 16 18 20 22 39 56 79 94 107 122 132 147 151 155 159 163 167 171 175 179 183 187 191 195 199 203 207 211 215 219 223 227 231 235 239 243 247 251 255 259 263 267 271 275 279 283 287 291 295 299 303 307 311 315 319 323 327 331 335 339 343 347 351 355 359 363 367 371 376 392"/>
    <cas:View sofa="1158" members="411 416 424 430 439 448 457 466 475 484 493 502 511 589 600 607 614 621 628 635 642 649 656 663 670 677 684 691 698 705 712 719 726 733 740 747 754 761 768 775 782 789 796 803 810 817 824 831 838 845 852 859 866 873 880 887 894 901 908 915 922 929 936 943 950 957 964 971 978 985 992 999 1006 1013 1020 1027 1034 1041 1048 1055 1062 1069 1076 1083 1090 1097 1104 1111"/>
    <cas:View sofa="1165" members="1146"/>
</xmi:XMI>
